2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Breast Neoplasms
70
Prostatic Neoplasms
50
Multiple Myeloma
30
Neoplasm Metastasis
28
Osteoporosis
16
Pain
15
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
10
Lung Neoplasms
8
Osteosarcoma
7
Neoplasms, Plasma Cell
7
Neuroblastoma
6
Carcinoma, Renal Cell
6
Bone Diseases, Metabolic
6
Humoral Hypercalcemia Of Malignancy
5
Bone Neoplasms
5
Fractures, Bone
4
Bone Diseases
4
Triple Negative Breast Neoplasms
3
Sarcoma, Ewing
3
Sarcoma
3
Lymphoma
3
Kidney Neoplasms
3
Uterine Cervical Neoplasms
2
Spinal Cord Compression
2
Small Cell Lung Carcinoma
2
Rhabdomyosarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pleural Effusion, Malignant
2
Ovarian Neoplasms
2
Interventions
Cyclophosphamide
23
blinatumomab
18
Cytarabine
16
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Blood Specimen Collection
8
Methotrexate
7
Lenalidomide
7
Dexamethasone
7
Daunorubicin
7
Mercaptopurine
6
Vincristine
5
daratumumab
4
Whole-Body Irradiation
4
Melphalan
4
Idarubicin
4
Etoposide
4
Drug Therapy
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Neoadjuvant Therapy
3
Maintenance
3
Liquid Biopsy
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Zoledronic Acid
×
Clear all
NCT00172068
2009-12-23
MRD-1
Novartis
Phase 2
Terminated
96 enrolled